Document:

EX-10.14

 Exhibit 10.14 

CONTRIBUTION AND EXCHANGE AGREEMENT 

THIS CONTRIBUTION AND EXCHANGE AGREEMENT (the
“Agreement”) is made effective as of the 1st day of September, 2020 (the “Contribution Date”) by and among the undersigned Shareholders (the “Shareholders”) of record of Monte Rosa Therapeutics AG,
a company incorporated in Switzerland, having its registered office at Aeschenvorstadt 36, 4051 Basel, Switzerland (“MRTx Swiss”) as of immediately prior to the Contribution and Exchange (as defined below), and
MONTE ROSA THERAPEUTICS, INC., a Delaware corporation (the “Company”). 

RECITALS 
 WHEREAS,
each Shareholder owns the number of shares of Common Shares, nominal value of CHF 0.01 per share, of MRTx Swiss (the “Common Shares”) as set forth next to such Shareholder’s name on Exhibit A attached hereto (such
shares the “Contribution Shares”); 
 WHEREAS, MRTx Swiss and each Shareholder are parties to both (i) that
certain Shareholders’ Agreement, dated as of April 10, 2018 (the “MRTx Swiss Shareholders’ Agreement”) and (ii) that certain Formation and Investment Agreement, dated as of April 10, 2018 (the “MRTx
Swiss Formation Agreement”); 
 WHEREAS, the Contribution Shares set forth on Exhibit A attached hereto represent
100% of the issued and outstanding share capital of MRTx Swiss held by the Shareholders as of immediately prior to the Contribution and Exchange; 

WHEREAS, concurrently with the execution of this Agreement, the Company and the Shareholders are entering into (i) a certain Right
of First Refusal and Co-Sale Agreement, dated April 14, 2020 (the “ROFR and Co-Sale Agreement”), (ii) a certain Voting Agreement, dated April 14, 2020 (the “Voting Agreement”) and (iii) a certain
Side Letter Agreement dated on or around the date hereof (the “Side Letter” and together with the ROFR and Co-Sale Agreement and the Voting Agreement, the “Transaction Agreements”); 

WHEREAS, each Shareholder desires to contribute, and the Company desires to acquire and accept, all of such Shareholder’s right,
title and interest in and to the Contribution Shares, and in consideration therefor such Shareholder shall receive that number of shares of Common Stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth
opposite such Shareholder’s name on Exhibit A (such shares, the “Consideration Shares”, and the contribution of the Contribution Shares in exchange for the Consideration Shares, the “Contribution and
Exchange”); and 
 WHEREAS, following the Contribution and Exchange, the Company shall be the sole owner of all of the
authorized, issued and outstanding share capital (as of the Contribution Date) of MRTx Swiss and as such, MRTx Swiss will be a wholly-owned subsidiary of the Company. 

WHEREAS, for U.S. federal income tax purposes, it is intended that: (i) the formation of the Company and (ii) the
Contribution and Exchange, taken together, constitute a tax-free contribution pursuant to Section 351 of the Internal Revenue Code of 1986, as amended, with respect to which each of MRTx Swiss and the Company are a party. MRTx Swiss, the
Company, and the Shareholders shall file all applicable U.S. tax returns consistent with the foregoing treatment. 

 NOW, THEREFORE, in consideration of the foregoing, and of the representations,
warranties, covenants and agreements contained herein, the parties hereto agree as follows: 
 ARTICLE I 

CONTRIBUTION AND EXCHANGE 

1.1 Closing. The closing of the transactions contemplated by this Agreement (the “Closing”) shall take place
simultaneously with the execution of this Agreement. Subject to the terms and conditions of this Agreement, each Shareholder hereby (i) agrees that the number of Contribution Shares set forth opposite such Shareholder’s name on Exhibit
A accurately reflects all of such Shareholder’s equity interests in MRTx Swiss and that such Shareholder does not hold (directly, indirectly, beneficially or otherwise in any respect) any equity interests in MRTx Swiss other than as set
forth opposite such Shareholder’s name on Exhibit A, (ii) agrees that such Shareholder is not entitled to any other equity of the Company other than the Consideration Shares set forth opposite such Shareholder’s name on
Exhibit A pursuant to the Contribution and Exchange; and (iii) grants, contributes, conveys, assigns, transfers and delivers to the Company, as of the Contribution Date, all of such Shareholder’s right, title and interest in and to
all of the Contribution Shares in all respects. 
 1.2 MRTx Shareholder Closing Deliverables. At the Closing, each Shareholder hereby
agrees to deliver to MRTx Swiss: 
 (a) duly executed instruments of transfer transferring its Contribution Shares to the Company signed by
each Shareholder as transferor; 
 (b) duly executed resolutions of the board of directors of MRTx Swiss approving the transfer of the
Contribution Shares to the Company, the registration of the Company as owner of record of the Contribution Shares in the MRTx Swiss’ share register; 

(c) duly executed countersignatures to each of the Transaction Agreements. 

1.3 Company Closing Deliverables. In exchange for the contribution of the Contribution Shares by each Shareholder, hereunder, at the
Closing, the Company shall deliver to MRTx Swiss: 
 (a) duly executed instruments of transfer with respect to all of
the Contribution Shares duly signed by the Company as transferee; and 
 (b) stock certificates of the Company representing
the Consideration Shares in the amounts as set forth opposite such Shareholder’s name on Exhibit A, which shares shall be duly authorized, validly issued, fully paid and nonassessable and issued in compliance with all applicable federal
and state securities laws. 

  
 2 

 1.4 Consent and Waiver by Shareholders. Each Shareholder hereby waives, with respect
to this Agreement or any other transaction contemplated hereby or thereby, any right of first refusal, co-sale right, and other similar rights, and any and all rights the Shareholder may have to notice in connection with such rights, under any
agreement to which the Shareholder is a party, including, but not limited to, the MRTx Swiss Shareholders’ Agreement and the MRTx Swiss Formation Agreement. Neither the execution and delivery of this Agreement by each Shareholder nor the
consummation of any of the transactions contemplated hereby or thereby does or will (i) in the case of any Shareholder that is an entity, conflict with or violate any provision of the certificate of incorporation, by-laws or similar
organizational documents of the Shareholder, (ii) require on the part of the Shareholder any notice to or filing with, or any permit, authorization, consent or approval of, any governmental entity, (iii) conflict with, result in a breach
of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of obligations or loss of any right or benefit under, create in any party the right to terminate, modify or cancel, or require any
notice, consent or waiver under, any contract or instrument to which the Shareholder is a party or by which the Shareholder is bound or to which any of the Shareholder’s assets is subject. 

ARTICLE II 

REPRESENTATIONS AND WARRANTIES BY THE SHAREHOLDERS 

Each Shareholder makes the following representations and warranties to the Company as of the Contribution Date: 

2.1 Ownership. Such Shareholder owns all right, title and interest (legal and beneficial) in and to all of the Contribution Shares set
forth opposite such Shareholder’s name on Exhibit A free and clear of all liens, including, but not limited to, any lien, pledge, claim, security interest, encumbrance, mortgage, assessment, charge, restriction or limitation of any kind,
whether arising by agreement, operation of law or otherwise, except for any and all restrictions on the transferability of the Common Shares (contained in the MRTx Swiss’ Articles of Association, as amended and in effect immediately prior to
the Contribution and Exchange, and the Shareholders Agreement, dated as of April 10, 2018, by and among MRTx Swiss and certain of the Shareholders, or otherwise) (the “Transfer Restrictions”) which have been waived or
terminated, those imposed by applicable securities laws and those described in Section 2.4 below. Such Shareholder has the full power and authority to contribute, transfer, convey, assign and deliver the Contribution Shares to the
Company, and upon delivery in accordance with the terms of this Agreement for the consideration expressed herein, on the Contribution Date, the Company shall acquire valid and unencumbered title to the Contribution Shares contributed by such
Shareholder. By executing this Agreement, such Shareholder further represents that such Shareholder does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any
third person, with respect to any of the Contribution Shares contributed by such Shareholder (other than the Transfer Restrictions, all of which have been waived or terminated). 

2.2 Valid Transfer of Shares. The Contribution Shares held by such Shareholder are free of restrictions on transfer, other than the
Transfer Restrictions, all of which have been waived or terminated. 

  
 3 

 2.3 Enforceability. This Agreement constitutes such Shareholder’s valid and
legally binding obligation, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights
generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. 

2.4 Consents. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with,
any foreign, state or local governmental authority or other party on the part of such Shareholder or MRTx Swiss is required in connection with the consummation of the transactions contemplated by this Agreement. 

2.5 No Violations. Neither the execution nor the delivery of this Agreement, nor the consummation of the transactions contemplated
hereby, will cause such Shareholder to be in violation or breach of, or default under, any term or provision of any mortgage, indebtedness, indenture, contract, agreement, instrument, judgment or decree to which it is a party or by which it is
bound. 
 2.6 Certain Securities Laws Representations. 

(a) Such Shareholder is acquiring and will hold the Consideration Shares for investment for his or her account only (including the account of
any affiliates and related investors to whom it attributes any of the Consideration Shares received by such Shareholder) and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the United
States Securities Act of 1933, as amended (the “Act”). 
 (b) Such Shareholder understands that the Consideration Shares
have not been registered under the Act by reason of a specific exemption therefrom and that the Consideration Shares must be held indefinitely, unless they are subsequently registered under the Act or such Shareholder obtains an opinion of counsel,
if reasonably requested, in form and substance satisfactory to the Company and its counsel, that such registration is not required. Such Shareholder further acknowledges and understands that the Company is under no obligation to register the
Consideration Shares. 
 (c) Such Shareholder is aware of the adoption of Rule 144 by the Securities and Exchange Commission under the Act,
which permits limited public resales of securities acquired in a non-public offering, subject to the satisfaction of certain conditions, including (without limitation) the availability of certain current public information about the issuer, the
resale occurring only after the holding period required by Rule 144 has been satisfied, the sale occurring through an unsolicited “broker’s transaction,” and the amount of securities being sold during any three-month period not
exceeding specified limitations. Such Shareholder acknowledges and understands that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company has no plans to satisfy these conditions in the foreseeable future. 

(d) Such Shareholder will not sell, transfer or otherwise dispose of the Consideration Shares in violation of the Act, the Securities Exchange
Act of 1934, or the rules promulgated thereunder, including Rule 144 under the Act. Such Shareholder agrees that he or she will not dispose of the Consideration Shares unless and until he or she has complied with all requirements of this Agreement
applicable to the disposition of Consideration Shares and he or she has provided the Company with written assurances, if reasonably requested, in substance and form satisfactory to the Company, that (A) the proposed disposition does not require
registration of the Consideration Shares under the Act or all appropriate action necessary for compliance with the registration requirements of the Act or with any exemption from registration available under the Act (including Rule 144) has been
taken and (B) the proposed disposition will not result in the contravention of any transfer restrictions applicable to the Consideration Shares under state securities law. 

  
 4 

 (e) Such Shareholder has been furnished with, and has had access to, such information as he
or she considers necessary or appropriate for deciding whether to invest in the Consideration Shares, and such Shareholder has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the
issuance of the Consideration Shares. 
 (f) Such Shareholder is aware that his or her investment in the Company is a speculative investment
that has limited liquidity and is subject to the risk of complete loss. Such Shareholder is able, without impairing his or her financial condition, to hold the Consideration Shares for an indefinite period and to suffer a complete loss of his or her
investment in the Consideration Shares. 
 2.7 Foreign Shareholders. Each Shareholder hereby represents that he, she or it has
satisfied itself as to the full observance of the laws of its jurisdiction in connection with the transactions contemplated by this Agreement, including (a) the legal requirements within its jurisdiction for the acquisition of the Consideration
Shares, (b) any foreign exchange restrictions applicable to such acquisition, (c) any governmental or other consents that may need to be obtained, and (d) the income tax and other tax consequences, if any, that may be relevant to the
acquisition, holding, redemption, sale, or transfer of the Consideration Shares or Contribution Shares, as applicable. Such Shareholder’s exchange for, and continued beneficial ownership of, the Consideration Shares will not violate any
applicable securities or other laws of such Shareholder’s jurisdiction. 
 2.8 Disqualification Event. None of the
“bad actor” disqualifications described in Rule 506(d)(1) of Regulation D under the Act apply to the Shareholder or any of its affiliates. In the event that any Disqualification Event applies to the Shareholder following the date hereof,
the Shareholder shall promptly advise the Company of such fact and furnish to the Company any supplementary information that may be requested. The Shareholder acknowledges and agrees that in the event that any Disqualification Event applies to the
Shareholder following the date hereof, the Company is permitted to disclose such Disqualification Event to the extent required by law. 

ARTICLE III 

REPRESENTATIONS AND WARRANTIES BY THE COMPANY 

As of the Contribution Date, the Company hereby represents and warrants to the Shareholders that: 

3.1 Authority. All corporate action on the part of the Company necessary for the authorization, execution and delivery of this
Agreement, the performance of all obligations of the Company hereunder, and the authorization, issuance and delivery of the Consideration Shares has been taken or will be taken prior to the Contribution and Exchange, and this Agreement, when
executed and delivered by the Company, will constitute a valid and legally binding obligation of the Company, enforceable in accordance with its terms. 

  
 5 

 3.2 Non-Contravention. The execution, delivery and performance of this Agreement, and
the consummation of the transactions contemplated hereby, will not result in any violation, default, conflict or breach of (a) any provision of its constitutive documents, or (b) in any material respect, any instrument, judgment, order,
writ, decree, or contract to which it is a party or by which it is bound nor will such consummation constitute, with or without the passage of time and giving of notice, an event that results in (a) the creation of any lien, charge or
encumbrance upon any assets of the Company, or (b) the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization, or approval applicable to the Company, its businesses or operations or any of
its assets or properties. 
 ARTICLE IV 

MISCELLANEOUS 
 4.1
Securities Law Restrictions. Regardless of whether the offering and sale of Consideration Shares under this Agreement have been registered under the Act or have been registered or qualified under the securities laws of any state, the Company at
its discretion may impose restrictions upon the sale, pledge or other transfer of the Consideration Shares (including the placement of appropriate legends on stock certificates or the imposition of stop-transfer instructions) if, in the judgment of
the Company, such restrictions are necessary or desirable in order to achieve compliance with the Act, the securities laws of any state or any other law. 

4.2 Transfer Restrictions. The Shareholders hereby agree and acknowledge that, effective as of the Contribution and Exchange, the
Common Stock issued to such Shareholders in connection therewith, will be subject to the transfer restrictions imposed on such Consideration Shares pursuant to the Company’s By-laws and the Transaction Agreements and hereby consent to such
transfer restrictions in all respects. 
 4.3 Legends. All certificates evidencing Consideration Shares shall, at the
Company’s discretion, bear one or all of the following legends, or legends that are substantially similar (together with any legend(s) required by the Transaction Agreements or applicable state “blue sky” securities laws, rules and
regulations): 
 “THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY
NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.” 

“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER CONTAINED IN THE BYLAWS OF THE CORPORATION.” 

  
 6 

 “THE COMPANY HAS MORE THAN ONE CLASS OF CAPITAL STOCK AUTHORIZED TO BE ISSUED. THE
COMPANY WILL FURNISH WITHOUT CHARGE TO EACH STOCKHOLDER UPON WRITTEN REQUEST A COPY OF THE FULL TEXT OF THE PREFERENCES, VOTING POWERS, QUALIFICATIONS AND SPECIAL AND RELATIVE RIGHTS OF THE SHARES OF EACH CLASS OF STOCK (AND ANY SERIES THEREOF)
AUTHORIZED TO BE ISSUED BY THE COMPANY AS SET FORTH IN ITS CHARTER AND ANY AMENDMENTS THERETO.” 
 4.4 Further Assurances. The
parties hereto agree that they will, at any time and from time to time after the Contribution Date and upon written request, do, execute acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered all such further acts,
deeds, assignments, transfers, conveyances, powers of attorney and assurances as may be reasonably required in conformity with this Agreement for the performance of the duties and obligations of each party to the other under this Agreement.

 4.5 Entire Agreement. This Agreement represents the entire contract between the parties with respect to the subject matter
hereof and supersedes all offers, proposals, statements, representations and agreements with respect to the subject matter hereof. This Agreement may not be amended except by action of each of the parties hereto set forth in an instrument in writing
signed on behalf of each of the parties hereto. 
 4.6 Captions. The captions to the Articles and sections contained in this
Agreement are for reference only, do not form a substantive part of this Agreement and shall not restrict nor enlarge any substantive provision of this Agreement. 

4.7 Governing Law; Waiver of Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this
Agreement (and any claims, issues, controversies or matters arising hereunder) shall be governed by the internal law of the State of Delaware without giving effect to any choice of law or conflict of law provision or rule (whether of the State of
Delaware or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Delaware. EACH PARTY (AFTER HAVING THE OPPORTUNITY TO CONSULT WITH COUNSEL) HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO
TRIAL BY JURY IN ANY LITIGATION, ACTION, PROCEEDING, CROSS-CLAIM, OR COUNTERCLAIM IN ANY COURT (WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE) ARISING OUT OF, RELATING TO OR IN CONNECTION WITH (I) THIS AGREEMENT OR THE VALIDITY, PERFORMANCE,
INTERPRETATION, COLLECTION OR ENFORCEMENT HEREOF OR (II) THE ACTIONS OF THE PARTIES IN THE NEGOTIATION, AUTHORIZATION, EXECUTION, DELIVERY, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF. 

  
 7 

 4.8 Jurisdiction and Venue. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY AGREES THAT
JURISDICTION AND VENUE IN ANY SUIT, ACTION OR PROCEEDING BROUGHT BY ANY PARTY ARISING OUT OF OR RELATING TO THIS AGREEMENT (INCLUDING ANY SUIT, ACTION OR PROCEEDING SEEKING EQUITABLE RELIEF) SHALL PROPERLY AND EXCLUSIVELY LIE IN THE COURT OF
CHANCERY OF THE STATE OF DELAWARE (THE “COURT OF CHANCERY”) OR, TO THE EXTENT THE COURT OF CHANCERY DOES NOT HAVE SUBJECT MATTER JURISDICTION, THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE AND THE APPELLATE COURTS
HAVING JURISDICTION OF APPEALS IN SUCH COURTS (THE “DELAWARE FEDERAL COURT”) OR, TO THE EXTENT NEITHER THE COURT OF CHANCERY NOR THE DELAWARE FEDERAL COURT HAS SUBJECT MATTER JURISDICTION, THE SUPERIOR COURT OF THE STATE OF DELAWARE
(COLLECTIVELY, THE “CHOSEN COURTS”). BY EXECUTION AND DELIVERY OF THIS AGREEMENT, EACH PARTY IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE CHOSEN COURTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY WITH RESPECT TO SUCH SUIT, ACTION OR
PROCEEDING. THE PARTIES HERETO IRREVOCABLY AGREE THAT VENUE WOULD BE PROPER IN THE CHOSEN COURTS, AND HEREBY WAIVE ANY OBJECTION THAT ANY SUCH CHOSEN COURT IS AN IMPROPER OR INCONVENIENT FORUM FOR THE RESOLUTION OF SUCH SUIT, ACTION OR PROCEEDING.

 4.9 Counterparts. This Agreement may be executed in any number of counterparts, and by facsimile or .pdf, each of which shall be
considered an original but all of which shall constitute but one and the same Agreement by and among the parties. 
 4.10
Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the other provisions hereof, and the Agreement shall be construed in all respects as if such invalid or unenforceable provisions were omitted.
Furthermore, upon the request of any party hereto, the parties to this Agreement shall add, in lieu of such invalid or unenforceable provisions, provisions as similar in terms to such invalid or unenforceable provisions as may be possible and legal,
valid and enforceable. 
 4.11 Amendment and Waiver. This Agreement may be amended or modified, and the observance of any term
hereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a written instrument executed by (a) the Company, (b) the Shareholders holding a majority of the shares of Common Stock
set forth on Exhibit A. 
 [Remainder of Page Intentionally Left Blank] 

  
 8 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the
day and year first above written. 
  

			
	COMPANY:
	
	MONTE ROSA THERAPEUTICS, INC.
		
	By:	 	 /s/ Markus Warmuth

	Name: Markus Warmuth
	Title:   President

  

 
			
	SHAREHOLDERS:
	
	CANCER RESEARCH TECHNOLOGY LIMITED
		
	By:	 	 /s/ Anthony Hickson

	Name: Anthony Hickson
	Title: Chief Business Officer
	
	THE INSTITUTE OF CANCER RESEARCH:
	ROYAL CANCER HOSPITAL
		
	By:	 	 /s/ Angela Kukula

	Name: Dr. Angela Kukula
	Title: Director of Enterprise
	
	 /s/ Rajesh Chopra

	Rajesh Chopra
	
	 /s/ Ian Collins

	Ian Collins

  
 10EX-10.15

 Exhibit 10.15 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

SERVICES AGREEMENT 

THIS SERVICES AGREEMENT (this “Agreement”),
effective as of 10 April, 2018 (the “Effective Date”), is by and between RIDGELINE THERAPEUTICS GMBH, a Basel
Switzerland corporation (“Ridgeline”), and MONTE ROSA THERAPEUTICS AG (in formation), a corporation to be registered
in Switzerland (the “Company”). 
 WHEREAS, Ridgeline is engaged in the
business of facilitating the start-up, funding and ongoing operation of new biotechnology companies and provides management, scientific, business development, clinical development and other operational
services to startup companies on a contract basis; and 
 WHEREAS, the Company is a drug discovery and
development company and desires to engage Ridgeline to provide the Company various services and make available to the Company certain resources of Ridgeline on the terms set forth herein. 

NOW, THEREFORE, in consideration of the above premises and for other good and valid
consideration, the receipt and adequacy of which are hereby acknowledged, the parties, intending to be legally bound, agree as follows: 

ARTICLE 1 

DEFINED TERMS 

1.1 “Company Confidential Information” shall mean (a) all Company Work Product and (b) any and all other
data, information, technology, samples and specimens relating to the Company or any other person or entity with which Company has a commercial relationship (other than Ridgeline) or their respective products, product concepts, technologies,
businesses, financial, marketing, clinical or regulatory affairs, manufacturing processes and procedures, or those of any other third party, whether written, graphic or oral, and whether or not furnished to or obtained by Ridgeline, either directly
or indirectly, during the course of performing Services hereunder; but excluding, in any event, Ridgeline Work Product. 
 1.2
“Company Work Product” shall mean any and all results (including data) and products (interim and/or final) of the Services performed by Ridgeline, whether tangible or intangible, including, without limitation, each and every
business, financial or other plan, computation, compilation of information, invention (whether or not patentable), discovery, design, drawing, protocol, process, technique, formula, trade secret, device, compound, substance, material,
pharmaceutical, method, software program (including without limitation, object code, source code, flow charts, algorithms and related documentation), listing, routine, manual and specification, whether or not patentable or copyrightable, that are
made, developed, perfected, designed, conceived or first reduced to practice by Ridgeline, either solely or jointly with others, in the course of the Services. 

  
 1 

 1.3 “Ridgeline Confidential Information” shall mean all data,
information, technology, samples and specimens relating to Ridgeline or any other person or entity with which Ridgeline has a commercial relationship (other than the Company) or their respective products, technologies, businesses, financial,
marketing, clinical or regulatory affairs, manufacturing processes and procedures, or those of any other third party, from whom Ridgeline receives information on a confidential basis, whether written, graphic or oral, furnished to or obtained by the
Company, either directly or indirectly, other than during the course of providing Services hereunder, including, without limitation, Ridgeline Work Product, but excluding Company Work Product. 

1.4 “Confidential Information” shall mean the Ridgeline Confidential Information or the Company’s Confidential
Information, as applicable. 
 1.5 “Ridgeline Key Team” shall mean those individuals set forth on Exhibit A
and such other individuals as may be agreed to between Ridgeline and the Company from time to time. 
 1.6 “Ridgeline
Work Product” shall mean any and all results (including data) and products (interim and/or final) of any activities or services performed by Ridgeline on behalf of itself or any third party, other than in the course of performing the
Services, whether tangible or intangible, including, without limitation, each and every invention (whether or not patentable), discovery, design, drawing, protocol, process, technique, formula, trade secret, device, compound, substance, material,
pharmaceutical, method, software program (including without limitation, object code, source code, flow charts, algorithms and related documentation), listing, routine, manual and specification, whether or not patentable or copyrightable, that are
made, developed, perfected, designed, conceived or first reduced to practice by Ridgeline, either solely or jointly with others, whether before, during or after the Term. 

1.7 “Term” shall have the meaning provided in Section 2.6. 

ARTICLE 2 

SERVICES 

2.1 Services. Subject to the terms of this Agreement, for the Term determined pursuant to Section 2.6(a) hereof, Ridgeline shall
provide or cause to be provided to the Company such services, in the nature of those described on Exhibit A, as may reasonably be requested by the Company and reasonably approved by Ridgeline from time to time following the date hereof (the
“Services”). 
 2.2 Charges and Payment. As compensation for its Services hereunder, the Company shall
pay Ridgeline in accordance with the provisions of Exhibit A attached hereto. In addition, the Company shall reimburse Ridgeline for its actual expenses (including travel expenses) as reasonably incurred by Ridgeline or its employees and/or
consultants in the course of performing Services. Ridgeline shall invoice the Company on a quarterly basis for all charges pursuant to this Agreement in accordance with the provisions of Exhibit A attached hereto. 

  
 2 

 2.3 General Obligations; Standard of Care. 

(a) Performance Requirements. Ridgeline shall use commercially reasonable efforts to provide Services subject to the terms of
this Agreement and in accordance with its policies, procedures and practices then in effect, and shall exercise substantially the same care and skill as it exercises in performing similar services for itself. 

(b) Changes. The parties acknowledge that Ridgeline may make changes from time to time in the manner of performing the Services
(e.g., if Ridgeline is making substantially similar changes in performing similar services for itself or its affiliates). To the extent they materially affect the Services, such changes shall be made in consultation with the Company. 

(c) Compliance. Ridgeline agrees to perform the Services in accordance with the terms and conditions contained in this Agreement
and in compliance with all applicable federal, state and local laws and regulations. 
 (d) Communication. On a regular basis
during the Term, the parties shall conduct meetings, either in person or by telephone or video conference, to discuss the progress and results of the Services. 

2.4 Confidentiality. 

(a) Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the parties,
the parties agree that, during the Term of this Agreement and for [***] thereafter, the receiving party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in
this Agreement any Confidential Information of the other party. Each party may use the other party’s Confidential Information only to the extent required to accomplish the purposes of this Agreement, consistent with any restrictions on the use
of Confidential Information received by a third party and communicated by the party disclosing such Confidential Information. To the extent that any such restrictions on the use of Confidential Information received by a third party exceed the
restrictions on the use of Confidential Information set forth in this’ Agreement, the parties each hereby agree to be bound by such restrictions. The parties agree and acknowledge that certain Confidential Information may be required for
submission to the U.S. Food and Drug Administration and/or federal or state regulatory bodies. The parties acknowledge and agree that such submissions, to the extent required by applicable law, shall not constitute a violation of the terms of this
Agreement if permitted under any applicable agreement with a third party for whom the disclosing party obtained the Confidential Information. Each party will use at least the same standard of care as it uses to protect proprietary or confidential
information of its own (but in no event less than reasonable care) to ensure that its employees, agents, consultants and other representatives do not disclose or make any unauthorized use of such Confidential Information. Each party will promptly
notify the other upon discovery of any unauthorized use or disclosure of such Confidential Information. 

  
 3 

 (b) Limitations. Confidential Information shall not include any information
that the receiving party can prove by competent evidence: (i) was already known to the receiving party without any obligations of confidentiality prior to receipt from the other party; (ii) was generally available to the public or
otherwise part of the public domain at the time of its disclosure to the receiving party; (iii) became generally available to the public or otherwise part of the public domain after its disclosure, other than through any act or omission of the
receiving party in breach of any obligation of confidentiality; (iv) was disclosed to the receiving party, other than under an obligation of confidentiality, by a third party who had no obligation not to disclose such information to others; or
(v) was independently discovered or developed by the receiving party without the use of Confidential Information; provided, however, that any combination of features or disclosures shall not be deemed to fall within the foregoing
exclusions solely because certain individual features are 
 (c) Authorized Disclosure. Notwithstanding Section 2.4(a), a
party may disclose Confidential Information of the other party, without violating the obligations of this Agreement, to the extent the disclosure is required by a valid order of a court or other governmental body having jurisdiction, provided that
such party gives reasonable prior written notice to the other party of such required disclosure and makes a reasonable effort to obtain, or to assist the other party in obtaining, a protective order preventing or limiting the disclosure and/or
requiring that the Confidential Information so disclosed be used only for the purposes for which the law or regulation requires, or for which the order was issued. 

(d) Use of Name/Publicity. Neither party shall use the other party’s name in connection with any publication or promotion
without the other party’s consent, except as required by federal, state or local laws, rules and regulations. Neither party shall disclose the specific content or terms of this Agreement without the prior written consent of the other party.

 2.5 Intellectual Property Rights 

(a) Ownership. The Company shall own all right, title and interest in and to all Company Work Product, including, without
limitation, all patent, copyright or other intellectual property rights therein, that is conceived or first reduced to practice by Ridgeline, either solely or jointly with others, in the course of performing the Services (collectively, the
“Company Intellectual Property”), and neither this Agreement, nor the provision of the Services hereunder, shall give Ridgeline any right, title or interest in or to any Company Intellectual Property. The Company shall be
responsible for all costs and expenses associated with such Company Work Product. The Company hereby grants to Ridgeline a non-exclusive, worldwide, fully-paid, royalty-free license, without the right to
sublicense, to use the Company’s technology solely as necessary or appropriate to perform Services under this Agreement during the Term. Ridgeline shall retain all right, title and interest in and to any and all Ridgeline Work Product,
including, without limitation, all patent, copyright or other intellectual property rights therein (collectively, the “Ridgeline Intellectual Property”), and neither this Agreement, nor the provision of the Services
hereunder, shall give the Company any right, title or interest in or to any Ridgeline Intellectual Property. 

  
 4 

 (b) Assignment; Assistance. Ridgeline hereby assigns all of Ridgeline’s
right, title and interest in and to any Company Intellectual Property to the Company without royalty or any other consideration and agrees to execute all applications, assignments or other instruments reasonably requested by the Company in order for
the Company to establish its ownership of such Company Intellectual Property and to obtain whatever protection for such Company Intellectual Property, including copyright and patent rights in any and all countries designated by the Company on such
Company Intellectual Property as the Company shall determine. Ridgeline agrees to assist the Company, or its designee, in every reasonable way (but at the Company’s expense) to secure the Company’s rights in Company Intellectual Property
and any copyrights, patents or other intellectual property rights relating to all Company Intellectual Property in any and all countries designated by the Company, including the disclosure to the Company of all pertinent information and data with
respect to all Company Intellectual Property, the execution of all applications, specifications, oaths, assignments and all other instruments that the Company may deem necessary in order to apply for and obtain such rights and in order to assign and
convey to the Company, its successors, assigns and nominees the sole and exclusive right, title and interest in and to all Company Intellectual Property. Ridgeline also agrees that its obligation to execute or cause to be executed any such
instrument or papers shall continue after the expiration or termination of this Agreement. Ridgeline agrees that, if the Company is unable because of Ridgeline’s unavailability, dissolution, or otherwise, to secure Ridgeline’s signature
for the purpose of applying for or pursuing any application for any United States or foreign patents or copyright registrations covering the Company Intellectual Property assigned to the Company herein, then, until such time Ridgeline becomes
available it hereby designates and appoints the Company and its duly authorized officers and agents as Ridgeline’s agent and attorney-in-fact, to act for and on
Ridgeline’s behalf to execute and file any such applications and to do all other lawfully permitted acts only to further the prosecution and issuance of patents and copyright registrations with the same legal force and effect as if executed by
Ridgeline. 
 2.6 Term; Termination. 

(a) Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and shall remain
in effect until terminated in accordance with this Section 2.6. 
 (b) Election to Terminate. The Company may terminate
this Agreement either with respect to all, or with respect to any one or more, of the Services provided hereunder (including, without limitation, terminating the provision of Services by any member or members of the Ridgeline Key Team) at any time
and from time to time, for any reason or no reason, by giving written notice to Ridgeline at least [***] prior to the date of such termination. Ridgeline may terminate this Agreement either with respect to all, or with respect to any one or more, of
the Services provided hereunder at any time and from time to time, for any reason or no reason, by giving written notice to the Company at least [***] prior to the date of such termination. In addition, the parties may at any time agree in writing
to terminate this Agreement with respect to some or all of the Services, effective immediately or as indicated in such writing. In the event of any termination with respect to one or more, but less than all, Services, this Agreement shall continue
in full force and effect with respect to any Services not terminated hereby. 
 (c) Payment Upon Early Termination. In the
event of termination of this Agreement or any Services hereunder, Ridgeline shall be paid for all work completed through the date of termination in accordance with this Agreement, including reasonable and documented out-of-pocket expenses and any non-cancelable commitments reasonably incurred by Ridgeline in accordance with this Agreement. Ridgeline shall refund to the Company any
prepaid amounts not earned by Ridgeline prior to the date of such termination, including as set forth in Section 2.2 hereof. 

  
 5 

 (d) Survival Upon Termination. Expiration or termination of this Agreement
will not relieve either party of any obligation accruing prior to such expiration or termination. Article 1, Sections 2.2, 2.4, 2.5, 2.6(c), 2.6(d), 3.3, 3.4, and Articles 4 and 5 will survive expiration or termination of this Agreement. 

ARTICLE 3 

REPRESENTATIONS AND WARRANTIES; DISCLAIMER; LIMITATION
OF LIABILITY 
 3.1 Mutual Representations and Warranties. Each party represents and
warrants to the other that: (a) it has full power and authority to enter into this Agreement and to perform its obligations hereunder; (b) this Agreement is legally binding upon it, enforceable against it in accordance with its terms, and
does not conflict with any charter or constituting document, or any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental
body or administrative or other agency having jurisdiction over it; and (c) such party is not under any pre-existing obligation inconsistent with the provisions of this Agreement. 

3.2 Ridgeline Representations and Warranties. Ridgeline hereby represents and warrants to the Company that the Services shall be
performed by qualified personnel in a good, timely, efficient and professional manner. 
 3.3 Disclaimer of Warranties. EXCEPT
AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. WITHOUT LIMITING THE GENERALITY OF THE
FOREGOING, AND EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, RIDGELINE MAKES NO REPRESENTATIONS OR WARRANTIES AS TO THE QUALITY, SUITABILITY OR ADEQUACY OF THE SERVICES FOR ANY PURPOSE OR USE. 

3.4 Limitation of Liability. NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT; provided, however, that this Section 3.4 shall not be construed to limit either party’s indemnification obligations under Article 4. 

ARTICLE 4 

INDEMNIFICATION 

4.1 By the Company. The Company hereby agrees to save, defend, indemnify and hold harmless Ridgeline, its affiliates and their
respective officers, directors, employees, consultants and agents (each, a “Ridgeline Party”) from and against any and all losses, damages, liabilities, expenses and costs, including reasonable legal expense and
attorneys’ fees “Losses”), to which any Ridgeline Party may become subject as a result of any claim, demand, action or other proceeding by any third party to the extent such Losses arise directly or indirectly out of
(a) the performance of the Services, (b) the development, manufacture, use, handling, storage, sale or other disposition of any product by the Company, or (c) the gross negligence or willful misconduct of any Company Party or the
breach by the Company of any warranty, representation, covenant or agreement made by the Company in this Agreement, except, in each case, to the extent such Losses result from the gross negligence or willful misconduct of any Ridgeline Party or the
breach by Ridgeline of any warranty, representation, covenant or agreement made by Ridgeline in this Agreement. 

  
 6 

 4.2 By Ridgeline. Ridgeline hereby agrees to save, defend, indemnify and hold
harmless the Company, its affiliates and their respective officers, directors, employees, consultants and agents (each, a “Company Party”) from and against any and all Losses to which any Company Party may become subject as a
result of any claim, demand, action or other proceeding by any third party to the extent such Losses arise directly or indirectly out of the gross negligence or willful misconduct of any Ridgeline Party or the breach by Ridgeline of any warranty,
representation, covenant or agreement made by Ridgeline in this Agreement, except, in each case, to the extent such Losses result from the gross negligence or willful misconduct of any Company Party or the breach by the Company of any warranty,
representation, covenant or agreement made by the Company in this Agreement. 
 4.3 Control of Defense. In the event a
party seeks indemnification under Section 4.1 or Section 4.2, it shall inform the other party (the “Indemnifying Party”) of a claim as soon as reasonably practicable after it receives notice of the claim, shall
permit the Indemnifying Party to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration with no admission of fault), and shall cooperate as requested (at the expense of the
Indemnifying Party) in the defense of the claim. 
 4.4 Liability Insurance. Each party agrees to maintain during the Term
usual and customary liability and workers compensation insurance in amounts consistent with industry standards and to provide a certificate of insurance evidencing such coverage to the other party upon request. 

ARTICLE 5 

MISCELLANEOUS 

5.1 Taxes. Ridgeline will pay any and all taxes levied on account of any payments made to it under this Agreement. If any taxes
are required to be withheld by the Company from any payment to Ridgeline, the Company shall (a) deduct such taxes from the payment, (b) timely pay the taxes to the proper taxing authority, and (c) send proof of payment to Ridgeline
and certify its receipt by the taxing authority within [***] following such payment. 
 5.2 Relationship of Parties. Nothing
in this Agreement shall be deemed or construed by the parties or any third party as creating the relationship of principal and agent, partnership or joint venture between the parties, it being understood and agreed that no provision contained
herein, and no act of the parties, shall be deemed to create any relationship between the parties other than the relationship of independent contractor nor be deemed to vest any rights, interest or claims in any third parties. 

  
 7 

 5.3 Integration. This Agreement (including the Exhibits hereto) contains the
complete, final and exclusive agreement of the parties relating to the subject matter hereof, and supersedes all prior and contemporaneous oral and written agreements or arrangements between the parties. To the extent this Agreement conflicts with
any other agreements, written or oral, between the parties, this Agreement controls. 
 5.4 Modification and Amendment. This
Agreement may not be modified or amended except in a writing signed by the parties. 
 5.5 Governing Law. This Agreement shall
be governed by and construed in accordance with the laws of Switzerland 
 5.6 No Implied Licenses. No right or license is
granted under this Agreement by either party to the other, either expressly or by implication, except those specifically set forth herein. 

5.7 Severability. If any provision of this Agreement should be held invalid or unenforceable, the remaining provisions shall be
unaffected and shall remain in full force and effect, to the extent consistent with the intent of the parties as evidenced by this Agreement as a whole. 

5.8 Assignment. Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be
assigned or otherwise transferred by either party without the prior written consent of the other party (which consent shall not be unreasonably withheld); provided, however, that the Company may assign this Agreement and its rights and
obligations hereunder without Ridgeline’s consent in connection with the transfer or sale of all or substantially all of the Company’s business to which this Agreement relates to a third party, whether by merger, sale of stock, sale of
assets or otherwise. The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the parties. Any assignment not in accordance with this Agreement shall be
void. 
 5.9 Headings. Section headings are for convenience of reference only and shall not be considered in the
interpretation of this Agreement. 
 5.10 Force Majeure. In the event of a delay caused by inclement weather, fire, flood,
strike or other labor dispute, act of God, act of governmental officials or agencies, or any other cause beyond the control of the parties, the party or parties so affected shall be excused from performance hereunder for the period of time
attributable to such delay, which may extend beyond the time lost due to one or more of the causes mentioned above. In the event of any such delay, the parties may, in their sole discretion, amend this Agreement, as appropriate, by mutual written
agreement. 
 5.11 Notices. Any notices required or permitted hereunder shall be given by overnight courier to the appropriate
party at the address specified below or at such other address as the party shall specify in writing. 

  
 8 

			
	 If to Ridgeline:
	  	 Ridgeline Therapeutics GmbH

Aeschenvorstadt 36, 4051 Basel, Switzerland

Attn: Dr. Alexander Mayweg

	 If to the Company:
	  	 Monte Rosa Therapeutics AG

Aeschenvorstadt 36, 4051 Basel, Switzerland

Attn: Chief Executive Officer

 All notices shall be deemed made upon receipt by the addressee as evidenced by the applicable written receipt.

 5.12 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and
all of which together shall constitute one and the same instrument. 
 5.13
Non-Waiver. No failure or delay of one of the parties to insist upon strict performance of any of its rights or powers under this Agreement shall operate as a waiver thereof, nor shall any other single
or partial exercise of such right or power preclude any other further exercise of any rights or remedies provided by law. 
 5.14
Waiver of Corporate Opportunity. In the event that either party to this Agreement or any director, officer, employee or representative of such party (the “Primary Party”) acquires knowledge of a potential transaction
or other matter (including, but not limited to, any compounds or other assets or the opportunity to acquire interests thereof) and that may be an opportunity of interest (a “Corporate Opportunity”) for the other party to this
Agreement (the “Other Party”), then the Other Party (i) renounces any expectancy that the Primary Party offer an opportunity to participate in such Corporate Opportunity to the Other Party and (ii) to the fullest
extent permitted by law, waives any claim that such opportunity constituted a Corporate Opportunity that should have been presented by the Primary Party to the Other Party or any of its affiliates. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 9 

 IN WITNESS WHEREOF, the
parties have executed this Services Agreement as of the date first above written. 
  

			
	RIDGELINE THERAPEUTICS GMBH
		
	By:	 	/s/ Alexander Mayweg 
	Name:	 	Alexander Mayweg
	Title:	 	CSO

  

			
	 MONTE ROSA THERAPEUTICS AG

(in formation)

		
	By:	 	/s/ Illegible 
	Name:	 	Illegible
		
	By:	 	/s/ Illegible 
	Name:	 	Illegible
		
	By:	 	/s/ Illegible 
	Name:	 	Illegible
	Title:	 	Company Secretary, Cancer Research Technology Limited
		
	By:	 	/s/ Illegible 
	Name:	 	Illegible
	Title:	 	Director, ICR

  

			
	 Versant Venture Capital VI, L.P.

By: Versant Ventures VI GP, L.P.
 By: Versant Ventures VI GP-GP, LLC

		
	By:	 	/s/ Bradley Bolzon 
	Name:	 	Bradley J. Bolzon
	Title:	 	Managing Director

 EXHIBIT A 

SERVICES 
 1. For
purposes of this Agreement, the “Ridgeline Key Team” shall initially mean Alexander Mayweg, CSO of Ridgeline, [***], and additional team members for scientific or laboratory expertise and work as required or required from
time to time in consultation with the Company. Subject to the provisions of Section 2.1 hereof, Ridgeline shall use commercially reasonable efforts to provide, among others, the following Services as may be requested from time to time by the
Company: 
  

	 	A.	 Set up services. Ridgeline shall or may procure any necessary set up services such as company
foundation, drafting or creation or refinement of business plan, capital equipment and infrastructure to perform Services for Company, including office equipment, IT systems and furniture. 

 

	 	B.	 Research and Development Services. Ridgeline shall or may provide to the Company general research and
development services pursuant to a research and development plan to be mutually agreed by the parties, including [***] 

  

	 	C.	 Management and Administrative Services. Ridgeline shall or may provide management, strategic and
administrative services, as mutually agreed by the parties, including: 

  

	 	i.	 [***]; 

  

	 	ii.	 [***]; 

  

	 	iii.	 [***]. 

  

	 	D.	 Other. Ridgeline shall provide such other Services as mutually agreed between Ridgeline and the Company.

 2. The Company shall pay Ridgeline per calendar quarter (or any partial quarter on a pro rata basis) for
Services to be performed pursuant to this Agreement. Unless otherwise mutually agreed to by Ridgeline and the Company in writing prior to the commencement of Services in any calendar quarter, Ridgeline shall invoice the Company for the actual
amounts incurred set forth in the table below (current estimates), on or about the [***] following each calendar quarter for the Services performed during the prior quarter, together with the amount of reimbursable costs and expenses incurred by
Ridgeline on behalf of the Company pursuant to Section 2.2 hereof prior to such invoice. The Company agrees to pay all amounts due to Ridgeline arising under this Agreement within [***] of receipt of any such invoice. 

3. In connection with the Services to be provided hereunder, the Company will issue to Ridgeline an allocation (to be agreed by the
Company board) of the Company’s Common Stock/Options Pool. Ridgeline may allocate and transfer such shares of the Company’s Common Stock to members of the Ridgeline Key Team from time to time according to an agreed vesting schedule, and
the Company agrees to use commercially reasonable efforts to provide all necessary consents and to facilitate any such transfer of such shares. 

 4. The Company and Ridgeline acknowledge that the fees payable for Services have been
set by reference to the costs expected to be incurred by Ridgeline in the provision of the Services to the Company, plus [***]. The currently projected cost estimates for Ridgeline set up, R&D (including drug discovery and design), management
and administrative services (excluding the [***]) are as follows, shown in millions CHF. These costs and timelines are subject to approval by the Company’s BOD and may be altered at the BOD level. 

 

	
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

 5. The Services fees and expense reimbursements shall be payable in CHF (Swiss Francs) (unless mutually
agreed by the parties) and shall be subject to all applicable government regulations and rulings. 
 6. The Company expressly
acknowledges that Ridgeline is engaged in the business of facilitating the start-up, funding and ongoing operation of multiple biotechnology companies and providing management, scientific, business
development, financial and other operational services to those companies and that neither Ridgeline nor any other company to which Ridgeline provides services shall have any exclusivity or similar obligation to the Company, including without
limitation any corporate opportunity obligation or any obligation to disclose or make available to the Company any information, potential transaction or other matter of which any such Ridgeline Party becomes aware otherwise than solely in the course
of performing Services under this Agreement on behalf of the Company. 

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]